Cantor Fitzgerald Predicts RNAC FY2025 Earnings

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for Cartesian Therapeutics in a research note issued to investors on Monday, March 17th. Cantor Fitzgerald analyst K. Kluska expects that the company will earn ($3.65) per share for the year. Cantor Fitzgerald has a “Hold” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is $4.56 per share.

Other research analysts have also recently issued reports about the company. HC Wainwright reduced their price target on Cartesian Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, March 14th. BTIG Research started coverage on Cartesian Therapeutics in a research report on Thursday, December 19th. They set a “buy” rating and a $42.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $41.00 price target on shares of Cartesian Therapeutics in a research report on Thursday, March 13th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.14.

Cartesian Therapeutics Stock Up 5.9 %

Shares of RNAC stock opened at $15.46 on Wednesday. The stock has a market cap of $400.52 million, a PE ratio of -0.29 and a beta of 0.71. Cartesian Therapeutics has a 52-week low of $11.67 and a 52-week high of $41.87. The business has a 50-day simple moving average of $18.43 and a 200-day simple moving average of $18.74.

Institutional Trading of Cartesian Therapeutics

A number of institutional investors have recently made changes to their positions in RNAC. FMR LLC boosted its stake in shares of Cartesian Therapeutics by 458.3% in the third quarter. FMR LLC now owns 2,851,830 shares of the company’s stock worth $45,972,000 after acquiring an additional 2,341,054 shares during the last quarter. Great Point Partners LLC acquired a new position in Cartesian Therapeutics during the third quarter worth $3,224,000. MPM Bioimpact LLC boosted its stake in Cartesian Therapeutics by 14.6% during the fourth quarter. MPM Bioimpact LLC now owns 721,139 shares of the company’s stock worth $12,916,000 after buying an additional 91,716 shares during the last quarter. Geode Capital Management LLC boosted its stake in Cartesian Therapeutics by 63.0% during the fourth quarter. Geode Capital Management LLC now owns 221,257 shares of the company’s stock worth $3,963,000 after buying an additional 85,557 shares during the last quarter. Finally, 683 Capital Management LLC boosted its stake in Cartesian Therapeutics by 65.7% during the fourth quarter. 683 Capital Management LLC now owns 125,000 shares of the company’s stock worth $2,239,000 after buying an additional 49,569 shares during the last quarter. 86.95% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CTO Metin Kurtoglu sold 2,458 shares of Cartesian Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $16.83, for a total value of $41,368.14. Following the sale, the chief technology officer now directly owns 62,258 shares of the company’s stock, valued at $1,047,802.14. The trade was a 3.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Blaine Davis sold 4,028 shares of Cartesian Therapeutics stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $16.83, for a total value of $67,791.24. Following the completion of the sale, the chief financial officer now directly owns 94,811 shares in the company, valued at $1,595,669.13. This represents a 4.08 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 14,744 shares of company stock worth $247,337 over the last three months. 57.90% of the stock is currently owned by corporate insiders.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.